|
|
 |
|
Bausch & Lomb
|
Bausch & Lomb is the eye health company. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world.
Bausch & Lomb has three product lines: Vision Care, Surgical, and Pharmaceuticals.
Bausch & Lomb's Vision Care business manufactures and markets the world's most comprehensive line of eye care products.
Soft and GP (gas permeable) contact lenses, Lens care products for soft and GP lenses,Eye drops and ointments, magnifiers and eyeglass accessories
Bausch & Lomb develops and markets prescription and over-the-counter drugs used to treat a wide range of eye conditions, including glaucoma, eye allergies, conjunctivitis, and dry eye.
|
|
Please choose the following products of Bausch & Lomb
|
|
|
|
|
Page:1 2 3 4 |
|
|
|
Today's News about Bausch & Lomb |
Bausch & Lomb near $9 bn sale to Valeant: source
An eye examination is performed on September 27, 2012 in Los Angeles, California. Canadian pharmaceutical company Valeant is close to a deal to acquire US eye health company Bausch & Lomb for about $9 ...
DealBook: Bausch & Lomb Said to Be Near $9 Billion Sale to Valeant
If completed, a transaction would be one of the biggest health care deals of the year. And it could reap a sizable profit for Bausch & Lomb’s current owner, Warburg Pincus.
Valeant Aims to Raise $1.75 Billion in Stock Sale, Outlines Debt Plans for Bausch & Lomb Deal
Valeant Aims to Raise $1.75 Billion in Stock Sale, Outlines Debt Plans for Bausch & Lomb Deal
Valeant Pharma plans $1.75B stock offering
Canadian drugmaker Valeant Pharmaceuticals International Inc. said Monday it will sell $1.75 billion in stock to help fund its acquisition of Bausch + Lomb. Valeant did not say how many shares it plans ...
Valeant to sell common shares to raise money for acquisition of Bausch + Lomb
MONTREAL - Pharmaceutical company Valeant (TSX:VRX) says it will sell common shares to raise roughly $1.75 billion in an effort to help pay for its US$8.7-billion acquisition of eye care company Bausch + Lomb.
Questions About Jobs In Bausch + Lomb Sale
Rochester, N.Y.— On Monday, Canadian pharmaceutical company Valeant announced it would buy Rochester-based Bausch + Lomb.
Bausch + Lomb To Be Sold to Canadian Drug Company
Rochester, N.Y. (AP) -- Canadian drugmaker Valeant Pharmaceuticals says it will buy eye-health company Bausch + Lomb for $8.7 billion in cash in a massive expansion of its ophthalmology business.
Bausch + Lomb sold to Valeant for $8.7 billion
Canadian drugmaker Valeant Pharmaceuticals said Monday that it will pay $8.7 billion to buy Bausch + Lomb, one of the world's best-known makers of contact lenses, in a massive expansion of Valeant's smaller ophthalmology business.
Valeant to buy Bausch + Lomb
Canadian drugmaker Valeant Pharmaceuticals said Monday that it will pay $8.7billion to buy Bausch + Lomb, one of the world's best-known makers of contact lenses, in a massive expansion of Valeant's smaller ophthalmology business.
Valeant near deal to acquire Bausch & Lomb: source
NEW YORK (Reuters) - Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch & Lomb Holdings Inc from Warburg Pincus LLC for about $9 billion, a person familiar with the matter said on Friday.
|
|
